KPTI insider filing: CFO receives 43,650 RSUs, 100% cliff vest in 2026

Q: When do the RSUs granted to KPTI’s CFO vest?

The 43,650 RSUs vest 100% on December 31, 2026 .

Q: How many KPTI shares does the reporting person own after the transaction?

Following the transaction, beneficial ownership is 54,316 shares .

Q: What is the conversion rate for the RSUs?

The RSUs convert into common stock on a one-for-one basis .

Q: Which equity plan governs this grant?

The grant was made under the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended .

Q: Did a reverse stock split affect the reported amounts?

Yes. Amounts reflect the one‑for‑fifteen reverse stock split effected on February 25, 2025 .

Q: What is the transaction date for this Form 4 event?

The transaction date is 10/15/2025 .

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Karyopharm Therapeutics (KPTI) reported an insider equity grant: EVP, CFO & Treasurer Lori Macomber received 43,650 restricted stock units (RSUs) on 10/15/2025 at a price of $0. The RSUs convert into common stock on a one-for-one basis and vest 100% on December 31, 2026. Following the award, her beneficial ownership stands at 54,316 shares. The reported share amounts reflect the company’s one‑for‑fifteen reverse stock split effected on February 25, 2025.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Macomber Lori

Role EVP, CFO & Treasurer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	43,650	$0.00	--

Holdings After Transaction: Common Stock — 54,316 shares (Direct)

Footnotes (1)

Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on December 31, 2026. Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

Form 4 Insider Transactions: What Each Field Means →

10/16/2025 - 12:00 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Macomber Lori

(Last)

(First)

(Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON

02459

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, CFO & Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/15/2025		A		43,650⁽¹⁾	A	$0	54,316⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on December 31, 2026.

2. Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

	/s/ Nancy Smith as Attorney-in-Fact for Lori Macomber	10/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did KPTI disclose in this Form 4 filing?

Karyopharm reported that its EVP, CFO & Treasurer, Lori Macomber, was granted 43,650 RSUs on 10/15/2025 at $0.

When do the RSUs granted to KPTI’s CFO vest?

The 43,650 RSUs vest 100% on December 31, 2026.

How many KPTI shares does the reporting person own after the transaction?

Following the transaction, beneficial ownership is 54,316 shares.

What is the conversion rate for the RSUs?

The RSUs convert into common stock on a one-for-one basis.

Which equity plan governs this grant?

The grant was made under the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended.

Did a reverse stock split affect the reported amounts?

Yes. Amounts reflect the one‑for‑fifteen reverse stock split effected on February 25, 2025.

What is the transaction date for this Form 4 event?

The transaction date is 10/15/2025.